LITTLETON, CO. November 15, 2018 — dBMEDx, Inc., a privately-held, wireless medical device company, announced today that it has entered into a definitive supply agreement with C. R. Bard, a subsidiary of BD (Becton, Dickinson and Company, NYSE: BDX). Under the agreement, Bard/BD will be the exclusive US distributor of the BBS RevolutionTM bladder scanner for the hospital and urology markets.
The dBMEDx BBS RevolutionTM bladder scanner was designed specifically for nurses and utilizes a novel, next generation 3D ultrasound scan engine that enables the first, fully automated bladder scanner. With its unmatched speed and simplicity, the BBS RevolutionTM is the ideal tool for today’s nurse-directed urinary care and bladder management protocols. The BBS RevolutionTM is FDA cleared, CE marked, and is commercially available in both the US and Europe.
“We are excited to work with Bard to broaden the availability of our new, automated scanning technology and help them provide the very best nursing tools to optimize patient care.” said David Shine, CEO of dBMEDx. ”Bard is the best in the business when it comes to clinical support and we are fortunate to have them as our partner.”
About dBMEDx, Inc.
dBMEDx is a privately held, growth stage, wireless medical device company focused on products to reduce healthcare acquired infections. The company has developed novel, automated scanning technology with a wide range of medical applications. The first commercial product with this technology is the BBS RevolutionTM bladder scanner, the first fully automatic bladder scanner, which was developed by the engineers who designed the original bladder scanning technology. The BBS RevolutionTM is manufactured in the USA and currently being sold in the US and Europe. For additional information, please visit http://www.dBMEDx.com.
SOURCE dBMEDx, Inc.
David Shine, CEO